DBV Technologies S.A. American Depositary Shares (DBVT) Stock
Key stats
- Market cap
- $746.55M
- Price / Earnings ratio
- -3.5x
- EPS (TTM)
- -$3.00
- Volume
- Loading
- 52-week high
- $26.19
- 52-week low
- $8.63
Source: third-party data provider, as of November 13, 2026
Compare with DBVT
Recent news

What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBVT

DBV Technologies Q2 Earnings Call Highlights
DBV Technologies Q2 Earnings Call Highlights
DBVT

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBVT

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
DBVT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 64.11
- MACD 12/26/9
- 0.11
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.32
- SMA 50
- $10.94
- Price above SMA 50
- EMA 50
- $11.09
- Price above EMA 50
- SMA 200
- $16.49
- Price below SMA 200
- EMA 200
- $15.22
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBVT

DBV Technologies Q2 Earnings Call Highlights
DBV Technologies Q2 Earnings Call Highlights
DBVT

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBVT

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
DBVT

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?
DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?
DBVT

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know
DBVT

DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy
DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy
DBVT

DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing
DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing
DBVT

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
DBVT
News tone: automated (AI) classification of the article's content, not a price prediction.
About DBV Technologies S.A. American Depositary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Tassé | CEO & Director | 1960 |
| Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer | 1969 |
| Dr. Pharis Mohideen M.D. | Chief Medical Officer | 1965 |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer | — |
| Mr. Jonathan Neely | VP & Head of Investor Relations | — |
| Ms. Michele F. Robertson | Chief Legal Officer | — |
| Mr. James Briggs | Chief Human Resources Officer | 1972 |
| Mr. Kevin Trapp | Chief Commercial Officer | 1967 |
| Alan Kerr | Senior VP & Head of Global Regulatory Affairs | — |
| Mr. Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 64.11
- MACD 12/26/9
- 0.11
- EMA 9 of MACD
- -0.21
- MACD histogram
- 0.32
- SMA 50
- $10.94
- Price above SMA 50
- EMA 50
- $11.09
- Price above EMA 50
- SMA 200
- $16.49
- Price below SMA 200
- EMA 200
- $15.22
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $46.00
- Average
- $46.50
- High
- $47.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.2 | -44.3 | ||||||||||
| 2022 | -13.6 | -15.2 | +20.5 | -18.9 | +9.0 | +65.6 | +6.7 | -19.9 | -8.3 | -14.6 | -14.0 | +10.1 |
| 2023 | -12.0 | +5.8 | +16.6 | -12.9 | +30.0 | -3.1 | -21.1 | -1.9 | -13.4 | -24.1 | -27.5 | +28.3 |
| 2024 | -3.2 | -7.9 | -9.8 | -15.1 | -18.8 | -32.0 | +18.6 | -5.3 | -19.5 | +6.6 | +2.4 | -22.2 |
| 2025 | +30.2 | +9.6 | +72.2 | +39.5 | -3.0 | +18.3 | -18.9 | +7.2 | +8.9 | +45.4 | -8.1 | +47.7 |
| 2026 | +13.4 | -2.8 | -10.2 | +2.4 | -3.9 | -12.8 | -14.2 | +1.8 | -12.4 | -15.3 | +31.3 |



